动脉化疗治疗浸润性膀胱癌现状及进展
摘要
随着治疗理念的进步和介入技术的发展,动脉化疗逐渐广泛应用于肌层浸润性膀胱癌保留膀胱的综合治疗,其联合手术及放疗等多种治疗模式可获得较好的预后,本文对动脉化疗的历史与发展、术前新辅助、术后辅助、药物方案、毒副反应及国内外动脉化疗治疗浸润性膀胱癌现状及进展做一综述。
引文
[1]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67:7-30.
[2]CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].Ca A Canc J Clin,2016,66(2):115.
[3]MILOWSKY M I,RUMBLE R B,BOOTH C M,et al.Guideline on muscle-invasive and metastatic bladder cancer(european association of urology guideline):american society of clinical oncology clinical practice guideline endorsement.[J].J Clin Oncol,2016,34(16):1945.
[4]PERDONSISTO,AUTORINO RICCARDO,DAMIANOROCCO et al.Bladder-sparing,combined-modality approach for muscle-invasive bladder cancer:a multi-institutional,long-term experience.[J].Cancer,2008,112(1):75-83.
[5]FAHMY N,APRIKIAN A,TANGUAY S,et al.Practice patterns and recurrence after partial cystectomy for bladder cancer[J].World J Urol,2010,28(4):419-423.
[6]王革芳.经导管动脉灌注化疗药物应用原则---中国肿瘤介入专家共识[J].介入放射学杂志,2017,30(11):963-970.
[7]STENZL A,COWAN NC,DE SANTIS M,et al.Treatment of muscle-invasive and metastatic bladder cancer:update of the EAU guidelines[J].Eur Urol,2012,59(6):1009-1018.
[8]TAKESHITA H,KIHARA K,MASUDA H,et al.Mp55-01bladder-sparing therapy in muscle-invasive bladder cancer by induction chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection:assessments of quality of life and urinary functions[J].J Urol,2014,191(4):e555-e555.
[9]杨彬,张雁钢,程伟,等.TURBt联合术前髂内动脉化疗栓塞术治疗大体积肌层浸润性膀胱癌的近期疗效分析[J].临床泌尿外科杂志,2016,33(8):710-712.
[10]李鸣,李宁忱,黄真,等.浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察[J].中华泌尿外科杂志,2004,25(10):662-664.
[11]梁胜杰,邹青松,韩邦旻等.新辅助动脉化疗在肌层浸润性大体积膀胱癌保留膀胱治疗中的价值[J].现代泌尿外科杂志,2014,19(8):517-520.
[12]HAN BANGMIN,LIANG SHENGJIE,JING YIFENG,et al.Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection[J].Med Oncol,2014,31(4):912.
[13]高飞.肌层浸润性膀胱癌保留膀胱手术的治疗进展[J].国际泌尿系统杂志,2015,35(1):104-106.
[14]BADALATO G M,GAYA J M,HRUBY G,et al.Immediate radical cystectomy vs conservative management for high grade cT1bladder cancer:is there a survival difference?[J].BJU Int,2012,110(10):1471.
[15]SMALDONE MC,JACOBS BL,SMALDONE AM,et al.Longterm results of selective partial cystectomy for invasive urothelial bladder carcinoma[J].Urology,2008,72(3):613.
[16]XIANG W U,TAO L I,LIN L,et al.Long-term efficacy of transurethral resection combined with intra-arterial chemotherapy in treating muscle-invasive bladder cancer[J].J Clin Urol,2016,23:38-39.
[17]MATSUMOTO Y,SAMMA S,FUKUI S,et al.External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer[J].Indian JUrol,2015,31(1):52-56.
[18]刘泽赋,叶云林,李向东,等.保留膀胱手术联合辅助动脉化疗治疗T2期膀胱癌的长期随访结果[J].中华泌尿外科杂志,2017,38(8):568-572.
[19]HASHINE K,KUSUHARA Y,MIURA N,et al.Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer[J].Jap J Clin Oncol,2009,39(6):381-386.
[20]杨彬,张雁钢,程伟,等.TURBt联合术前髂内动脉化疗栓塞术治疗大体积肌层浸润性膀胱癌的近期疗效分析[J].临床泌尿外科杂志,2016,33(8):710-712.
[21]CHISM DAVID D,WOODS MICHAEL E,Milowsky Matthew I.Neoadjuvant paradigm for accelerated drug development:an ideal model in bladder cancer[J].Oncologist,2013,18(8):933-40.
[22]LIANG S,ZOU Q,HAN B,et al.Intra-Arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection[J].Urologia Internationalis,2015,94(4):406-411.
[23]AKAZA H,NAITO S,USAMI M,et al.Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy:a Japanese experience.[J].Jap J Clin Oncol,2007,37(3):201.
[24]MIYATA Y,NOMATA K,OHBA K,et al.Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer:a singlecentre study of 163patients[J].Eur J Surg Oncol,2015,41(3):361.
[25]张国辉,王金萍,郑清友,等.肌层浸润性膀胱癌保留膀胱手术后不同辅助治疗方法的疗效评价[J].现代泌尿外科杂志,2013,18(6):557-561.
[26]杨庆亚,谢天朋,许清泉,等.不同化疗方式预防浅表性膀胱癌术后复发的疗效和安全性[J].实用医学杂志,2015,47(5):795-798.
[2]CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].Ca A Canc J Clin,2016,66(2):115.
[3]MILOWSKY M I,RUMBLE R B,BOOTH C M,et al.Guideline on muscle-invasive and metastatic bladder cancer(european association of urology guideline):american society of clinical oncology clinical practice guideline endorsement.[J].J Clin Oncol,2016,34(16):1945.
[4]PERDONSISTO,AUTORINO RICCARDO,DAMIANOROCCO et al.Bladder-sparing,combined-modality approach for muscle-invasive bladder cancer:a multi-institutional,long-term experience.[J].Cancer,2008,112(1):75-83.
[5]FAHMY N,APRIKIAN A,TANGUAY S,et al.Practice patterns and recurrence after partial cystectomy for bladder cancer[J].World J Urol,2010,28(4):419-423.
[6]王革芳.经导管动脉灌注化疗药物应用原则---中国肿瘤介入专家共识[J].介入放射学杂志,2017,30(11):963-970.
[7]STENZL A,COWAN NC,DE SANTIS M,et al.Treatment of muscle-invasive and metastatic bladder cancer:update of the EAU guidelines[J].Eur Urol,2012,59(6):1009-1018.
[8]TAKESHITA H,KIHARA K,MASUDA H,et al.Mp55-01bladder-sparing therapy in muscle-invasive bladder cancer by induction chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection:assessments of quality of life and urinary functions[J].J Urol,2014,191(4):e555-e555.
[9]杨彬,张雁钢,程伟,等.TURBt联合术前髂内动脉化疗栓塞术治疗大体积肌层浸润性膀胱癌的近期疗效分析[J].临床泌尿外科杂志,2016,33(8):710-712.
[10]李鸣,李宁忱,黄真,等.浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察[J].中华泌尿外科杂志,2004,25(10):662-664.
[11]梁胜杰,邹青松,韩邦旻等.新辅助动脉化疗在肌层浸润性大体积膀胱癌保留膀胱治疗中的价值[J].现代泌尿外科杂志,2014,19(8):517-520.
[12]HAN BANGMIN,LIANG SHENGJIE,JING YIFENG,et al.Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection[J].Med Oncol,2014,31(4):912.
[13]高飞.肌层浸润性膀胱癌保留膀胱手术的治疗进展[J].国际泌尿系统杂志,2015,35(1):104-106.
[14]BADALATO G M,GAYA J M,HRUBY G,et al.Immediate radical cystectomy vs conservative management for high grade cT1bladder cancer:is there a survival difference?[J].BJU Int,2012,110(10):1471.
[15]SMALDONE MC,JACOBS BL,SMALDONE AM,et al.Longterm results of selective partial cystectomy for invasive urothelial bladder carcinoma[J].Urology,2008,72(3):613.
[16]XIANG W U,TAO L I,LIN L,et al.Long-term efficacy of transurethral resection combined with intra-arterial chemotherapy in treating muscle-invasive bladder cancer[J].J Clin Urol,2016,23:38-39.
[17]MATSUMOTO Y,SAMMA S,FUKUI S,et al.External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer[J].Indian JUrol,2015,31(1):52-56.
[18]刘泽赋,叶云林,李向东,等.保留膀胱手术联合辅助动脉化疗治疗T2期膀胱癌的长期随访结果[J].中华泌尿外科杂志,2017,38(8):568-572.
[19]HASHINE K,KUSUHARA Y,MIURA N,et al.Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer[J].Jap J Clin Oncol,2009,39(6):381-386.
[20]杨彬,张雁钢,程伟,等.TURBt联合术前髂内动脉化疗栓塞术治疗大体积肌层浸润性膀胱癌的近期疗效分析[J].临床泌尿外科杂志,2016,33(8):710-712.
[21]CHISM DAVID D,WOODS MICHAEL E,Milowsky Matthew I.Neoadjuvant paradigm for accelerated drug development:an ideal model in bladder cancer[J].Oncologist,2013,18(8):933-40.
[22]LIANG S,ZOU Q,HAN B,et al.Intra-Arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection[J].Urologia Internationalis,2015,94(4):406-411.
[23]AKAZA H,NAITO S,USAMI M,et al.Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy:a Japanese experience.[J].Jap J Clin Oncol,2007,37(3):201.
[24]MIYATA Y,NOMATA K,OHBA K,et al.Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer:a singlecentre study of 163patients[J].Eur J Surg Oncol,2015,41(3):361.
[25]张国辉,王金萍,郑清友,等.肌层浸润性膀胱癌保留膀胱手术后不同辅助治疗方法的疗效评价[J].现代泌尿外科杂志,2013,18(6):557-561.
[26]杨庆亚,谢天朋,许清泉,等.不同化疗方式预防浅表性膀胱癌术后复发的疗效和安全性[J].实用医学杂志,2015,47(5):795-798.